H. Lundbeck, Lundbeck and Cephalon initiate clinical trial of CEP-1347 for the treatment of Parkinson’s disease

H. Lundbeck A/S and Cephalon, Inc. announced today the start of a large North American clinical trial of CEP-1347 in patients with early stage Parkinson’s disease. The study expects to enrol approximately 800 patients at up to 65 locations in the United States and Canada.


Documents & Links